Hjem › Myelogen leukemi i kronisk fase › Texas
Kliniske studier for Myelogen leukemi i kronisk fase i Texas
6 studier for Myelogen leukemi i kronisk fase søker deltakere på steder i Texas.
Byer i Texas
Offisiell studietekst (engelsk)
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT01746836Study of Olverembatinib (HQP1351) in Patients With CML-CP
- Ascentage Investigative Site #1051, Amarillo
- Ascentage Investigative Site #1036, Austin
- Ascentage Investigative Site #1501, Houston
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06423911Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 15 til 80 · Alle kjønn · Oppdatert 30. jul. 2026 · NCT02727803A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
- Baylor Scott and White Research, Temple
RekruttererObservasjonsstudie
Alder 18 til 100 · Alle kjønn · Oppdatert 20. jul. 2026 · NCT07091019A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. apr. 2026 · NCT05304377A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
- The University of Texas M.D. Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 12. jan. 2026 · NCT06163430Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.